You just read:

Maxwell Biotech Venture Fund's Portfolio Company Hepatera LLC Announces Positive Interim Results of Phase 2b Clinical Program of Myrcludex B

News provided by

Maxwell Biotech Venture Fund

Nov 28, 2017, 10:07 EST